Processa Pharmaceuticals Files 8-K on Shareholder Votes & Financials
Ticker: PCSA · Form: 8-K · Filed: Jul 2, 2024 · CIK: 1533743
| Field | Detail |
|---|---|
| Company | Processa Pharmaceuticals, Inc. (PCSA) |
| Form Type | 8-K |
| Filed Date | Jul 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting
TL;DR
Processa Pharma filed an 8-K on 6/28/24 for shareholder votes & financials. All good.
AI Summary
Processa Pharmaceuticals, Inc. filed an 8-K on July 2, 2024, reporting on matters submitted to a vote of security holders and financial statements as of June 28, 2024. The filing details the company's corporate structure and principal executive offices in Hanover, Maryland.
Why It Matters
This 8-K filing provides crucial updates on Processa Pharmaceuticals' corporate governance and financial reporting, which are important for investors to assess the company's current status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not indicate any immediate financial distress or significant operational changes.
Key Players & Entities
- Processa Pharmaceuticals, Inc. (company) — Registrant
- June 28, 2024 (date) — Date of earliest event reported
- July 2, 2024 (date) — Date of report
- Hanover, Maryland (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.
What is the primary business of Processa Pharmaceuticals, Inc.?
Processa Pharmaceuticals, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
When was the company incorporated?
The company was incorporated in Delaware.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What was the former name of Processa Pharmaceuticals, Inc.?
The former name of Processa Pharmaceuticals, Inc. was Heatwurx, Inc., with a date of name change on October 28, 2011.
Filing Stats: 653 words · 3 min read · ~2 pages · Grade level 13.4 · Accepted 2024-07-01 19:44:30
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share PCSA Nasdaq Ca
Filing Documents
- form8-k.htm (8-K) — 54KB
- 0001493152-24-025884.txt ( ) — 226KB
- pcsa-20230628.xsd (EX-101.SCH) — 3KB
- pcsa-20230628_lab.xml (EX-101.LAB) — 33KB
- pcsa-20230628_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROCESSA PHARMACEUTICALS, INC. Date: July 1, 2024 By: /s/ James Stanker James Stanker Chief Financial Officer